Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Ion Channels as Targets for an anti- Tick Vaccine

Award Number: F30AI197381
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 08/06/2026
PERIOD OF PERFORMANCE END DATE: 08/05/2030

Group Awards By:

View Award Description

Ion Channels as Targets for an anti- Tick Vaccine - Abstract: The prevalence of tick-borne diseases in the United States is on the rise, necessitating innovative solutions. Anti-tick vaccines can contribute to vector control and mitigate the spread of tick-borne illnesses by inducing host immunity to targets in tick saliva or within the tick itself. While these approaches have shown some success, they require further optimization. We propose an innovative strategy to enhance the efficacy of anti-tick vaccines by inducing antibodies against the tick ion channels that have traditionally been targeted by small molecules. Previous work demonstrated that anti-Glutamate Gated Chloride Channel (GluCl) antibodies exhibited toxicity in mosquitoes but were limited by their inability to exit the midgut and bind to their targets in the periphery. Our preliminary data replicate this toxicity in ticks. Microinjections of purified polyclonal antibodies from mice vaccinated with tick GluCl peptides induced mortality that was statistically indistinguishable from the small molecule positive control and three times greater than the negative control antibodies. GluCl is exceptionally conserved among ticks and is absent in vertebrates, making it a potential target for broad-spectrum tick control. Ticks allow orders of magnitude more antibody “leakage” into the hemolymph compared to mosquitoes, sensitizing them to this approach. If the baseline level of antibody leakage is insufficient, there is a means to increase gut leakage: vaccination with Bm86. Bm86 was previously used as a commercial anti-tick vaccine against the economically significant Rhipicephalus microplus tick. This vaccination promotes substantial leakage of the tick gut when feeding on a vaccinated host, although it was held back by only exerting this effect in R.microplus ticks. As a proof of concept, we propose combining vaccination with GluCl and Bm86 and conducting testing on the R.microplus tick as a model system to ensure that naturally ingested antibodies against GluCl have the greatest opportunity to reach their target and exert their toxic effect. In parallel, we propose screening other tick ion channels as potential vaccine targets to assess of tick-killing antibodies are also induced. This Fellowship Grant and training plan is well designed to prepare me to become a superlative infectious disease physician and a leading expert in ticks and vector control in the United States. Ticks and vector-borne diseases are poised to be a grave public health concern in the coming decades and there are not enough physician scientists to meet the threat of tick-borne disease in that time. My project, studying ticks themselves and developing an innovative means to control them, circumvents the heterogeneity of tick-borne diseases by focusing on the vectors that these diverse diseases share as a common mode of introduction to humans. By funding my fellowship, you will be investing in an individual with a track record of success and committed to developing effective ways to protect Americans from the looming threat that tick-borne diseases pose.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $51,477 )
2026	2026	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	001	1	8/6/2026	NEW	$0
2026	2026	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	000	1	8/6/2026	NEW	$51,477
														Subtotal = $51,477

Grand Total All Awards = $51,477

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Ion Channels as Targets for an anti- Tick Vaccine

Award Number: F30AI197381

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 08/06/2026

PERIOD OF PERFORMANCE END DATE: 08/05/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer